Filing summary
Issuer and period: The supplied filing is Ocuphire Pharma, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2022, filed November 4, 2022. This differs from the request metadata, which names Opus Genetics; verify the intended company before relying on this summary.
Business context
Ocuphire is a clinical-stage ophthalmic biopharmaceutical company with no products approved for sale and no significant recurring revenue. Its lead candidate, Nyxol, is being developed for several vision disorders; APX3330 is being studied for diabetic retinopathy and diabetic macular edema. The company also has second-generation APX candidates and legacy RX-3117 licensing arrangements.
Financial performance and position
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | $0 in 2022; $0.489 million in 2021 | $0 in 2022; $0.589 million in 2021 |
| Operating expenses | $4.538 million in 2022; $4.721 million in 2021 | $15.984 million in 2022; $17.144 million in 2021 |
| Net loss | $4.531 million in 2022; $4.230 million in 2021 | $16.053 million in 2022; $50.380 million in 2021 |
| Net loss per share | $0.22 in 2022; $0.25 in 2021 | $0.82 in 2022; $3.64 in 2021 |
| Cash used in operations | Not stated for the quarter | $14.477 million in 2022; $13.724 million in 2021 |
At September 30, 2022, cash and cash equivalents were $13.855 million, short-term investments were $0.101 million, total current assets were $14.561 million, and total current liabilities were $2.691 million. Total assets were $14.568 million and stockholders’ equity was $11.877 million. The $0.538 million short-term loan outstanding at year-end 2021 was repaid in May 2022; no debt was reported at quarter-end. The filing does not provide a meaningful gross margin measure, as there was no current-period revenue.
Changes versus prior period
- Quarterly net loss increased by $0.301 million year over year, despite operating expenses falling $0.183 million, principally because the comparable 2021 quarter included $0.489 million of collaboration revenue.
- Nine-month net loss improved by $34.327 million, largely because 2021 included a $33.829 million noncash warrant-liability fair-value expense. Operating loss improved by $0.571 million; the current-period result should not be read as evidence of profitability.
- Nine-month R&D expense rose $0.332 million to $10.769 million, reflecting timing of trials and manufacturing plus regulatory and other development work. G&A fell $1.492 million, mainly because 2021 included a $1.6 million noncash investor settlement.
- Cash declined $10.679 million from $24.534 million at December 31, 2021. Nine-month financing provided $3.798 million, primarily from ATM share sales, compared with $19.575 million in 2021.
Outlook, risks, and unusual items
- Management expected available cash to fund operations into the fourth quarter of 2023, but the company disclosed substantial doubt about its ability to continue as a going concern and said additional financing is needed. Funding may not be available on acceptable terms; equity financing would dilute shareholders.
- Management anticipated an NDA submission for Nyxol in Q4 2022 under the 505(b)(2) pathway and began pre-commercialization planning. The FDA granted a waiver of the $3.1 million PDUFA fee. These are forward-looking plans, not evidence of approval.
- Ocuphire reported completion of final patient visits in the APX3330 ZETA-1 Phase 2b trial and expected top-line results in early 2023. It anticipated initiating the first Nyxol presbyopia Phase 3 trial in Q4 2022, with additional trials planned for 2023.
- Management expects R&D and G&A costs to increase as trials advance and regulatory, manufacturing, staffing, and potential commercialization needs grow. Clinical outcomes, regulatory review, trial timing, supply constraints, inflation, and capital-market access are key uncertainties.
- The company raised $4.428 million gross through ATM sales during the first nine months of 2022, issuing 1,848,980 shares. As of September 30, 20,801,506 shares were outstanding; multiple warrant and option instruments could create additional dilution.
- Potential Apexian license obligations include up to $11 million in development and regulatory milestones, up to $20 million in sales milestones, and single-digit royalties; no milestone or royalty obligations had been triggered. No material legal proceedings were reported. The headquarters lease was extended in October 2022 through December 31, 2023.
Most important facts to verify
- Confirm that Ocuphire Pharma—not Opus Genetics—is the intended issuer.
- Check subsequent cash use, financing, and actual runway against management’s Q4 2023 estimate and the going-concern warning.
- Verify whether the Nyxol NDA was submitted as planned and the status and outcomes of FDA review and planned clinical trials.
- Review updated APX3330 ZETA-1 results and any changes to development plans or costs.
- Assess remaining ATM capacity, subsequent equity issuance, and the potential dilution from outstanding warrants and options.